首页> 外文期刊>Vox Sanguinis: International Journal of Blood Transfusion and Immunohaematology >A new method of concentrating hepatitis B virus (HBV) DNA and HBV surface antigen: an application of the method to the detection of occult HBV infection.
【24h】

A new method of concentrating hepatitis B virus (HBV) DNA and HBV surface antigen: an application of the method to the detection of occult HBV infection.

机译:浓缩乙型肝炎病毒(HBV)DNA和HBV表面抗原的新方法:该方法在隐性HBV感染检测中的应用。

获取原文
获取原文并翻译 | 示例
           

摘要

Background The risk of post-transfusion hepatitis B virus (HBV) infection has been reduced after the implementation of HBV nucleic acid amplification technology (NAT). However, the problem of HBV DNA-positive and HBV surface antigen (HBsAg)-negative occult HBV infections remains to be solved. This is in part due to the HBV DNA load being too low to detect these occult HBV infections using mini-pool NAT. In Japan, the assay for the antibody against the HBV core antigen (anti-HBc) has not completely excluded occult HBV infection. To solve this problem, we have developed a new method of concentrating HBV DNA and HBsAg simultaneously to increase the sensitivity of detection tests. Methods Virus concentration is achieved by the enhancement of the agglutination of viruses using poly-L-lysine in the presence of a bivalent metal. Poly-L-lysine-coated magnetic beads are used to shorten the time of each step of the concentration procedure. Seventy-seven anti-HBc-positive and HBsAg-negative donations were examined. HBsAg and anti-HBc were tested by enzyme immunoassay (EIA) (AxSYM; Abbott) and haemagglutination inhibition test (Japanese Red Cross), respectively. Results HBV surface antigen and HBV DNA levels were concentrated up to four- to sevenfold. Using this method, 35 of the 77 anti-HBc-positive and HBsAg-negative donors were HBV DNA-positive by individual NAT and a further five donors became HBV DNA-positive by HBV concentration. Twenty-seven of 40 occult HBV infections became HBsAg-positive by HBsAg concentration. Conclusion Our new method of concentrating HBV and HBsAg increased the sensitivities of EIA and HBV NAT, and enabled us to detect 27 of 40 occult HBV infections by HBsAg EIA.
机译:背景技术实施HBV核酸扩增技术(NAT)后,输血后乙型肝炎病毒(HBV)感染的风险已降低。但是,HBV DNA阳性和HBV表面抗原(HBsAg)阴性的隐匿性HBV感染问题仍需解决。部分原因是由于HBV DNA负载过低,无法使用微型池NAT检测这些隐匿性HBV感染。在日本,针对HBV核心抗原的抗体(抗HBc)的检测方法并未完全排除隐匿性HBV感染。为了解决这个问题,我们开发了一种同时浓缩HBV DNA和HBsAg的新方法,以提高检测测试的灵敏度。方法通过在二价金属存在下使用聚-L-赖氨酸增强病毒的凝集作用来实现病毒浓缩。使用聚-L-赖氨酸包被的磁珠可缩短浓缩过程每个步骤的时间。检查了77例抗HBc阳性和HBsAg阴性的捐赠者。 HBsAg和抗HBc分别通过酶免疫法(EIA)(AxSYM; Abbott)和血凝抑制试验(日本红十字会)进行测试。结果HBV表面抗原和HBV DNA水平被浓缩至四至七倍。使用这种方法,通过单独的NAT,在77个抗HBc阳性和HBsAg阴性的供体中,有35个为HBV DNA阳性,而另外5个供体的HBV浓度则为HBV DNA阳性。通过HBsAg浓度,在40例隐匿性HBV感染中有27例变为HBsAg阳性。结论我们的浓缩HBV和HBsAg的新方法提高了EIA和HBV NAT的敏感性,使我们能够检测到40例HBsAg EIA隐匿性HBV感染中的27例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号